GSKproduct launch
The FDA granted accelerated approval to GSK Plc.’s Nelkarmi for pretreated ALK-positive non-small cell lung cancer, marking the company's second lung cancer drug approval this year.
Benzinga
2 stories shown
The FDA granted accelerated approval to GSK Plc.’s Nelkarmi for pretreated ALK-positive non-small cell lung cancer, marking the company's second lung cancer drug approval this year.
GSK has received FDA accelerated approval for neladalkib, a lung cancer therapy acquired through its purchase of Nuvalent.